Stockscreener 앱 받기
2.38
0.83%
-0.02
전일 마감가:
$2.40
열려 있는:
$2.36
하루 거래량:
38,896
Relative Volume:
0.27
시가총액:
$40.40M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-5.56%
1개월 성능:
-11.52%
6개월 성능:
-73.47%
1년 성능:
+0.00%
1일 변동 폭
$2.35
$2.53
1주일 범위
$2.32
$2.5309
52주 변동 폭
$1.70
$19.40
Onkure Therapeutics Inc Stock (OKUR) Company Profile
명칭
Onkure Therapeutics Inc
전화
(720) 307-2892
주소
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
OKUR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
2.38 | 40.40M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-30 | 개시 | Evercore ISI | Outperform |
| 2024-12-05 | 개시 | Leerink Partners | Outperform |
| 2024-10-10 | 개시 | Oppenheimer | Outperform |
| 2023-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-12-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-12-14 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-12-14 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2023-12-14 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-12-14 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-12-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-11-15 | 개시 | William Blair | Outperform |
| 2023-08-28 | 개시 | H.C. Wainwright | Buy |
| 2023-07-03 | 개시 | BofA Securities | Buy |
| 2022-09-19 | 재개 | H.C. Wainwright | Buy |
| 2022-01-27 | 개시 | Robert W. Baird | Outperform |
| 2021-12-21 | 개시 | H.C. Wainwright | Buy |
| 2021-11-22 | 개시 | Ladenburg Thalmann | Buy |
| 2021-05-04 | 개시 | Jefferies | Buy |
| 2021-05-04 | 개시 | Piper Sandler | Overweight |
| 2021-05-04 | 개시 | SVB Leerink | Outperform |
모두보기
Onkure Therapeutics Inc 주식(OKUR)의 최신 뉴스
Two Sigma Advisers LP Invests $122,000 in OnKure Therapeutics (NASDAQ:OKUR) - Defense World
Millennium Management LLC Acquires New Shares in OnKure Therapeutics (NASDAQ:OKUR) - Defense World
Northern Trust Corp Purchases New Position in OnKure Therapeutics (NASDAQ:OKUR) - Defense World
Buy Rating for OnKure Therapeutics Driven by Promising Developments in Metastatic Breast Cancer Treatment and Strong Financial Position - TipRanks
Bank of America Corp DE Takes $2.15 Million Position in OnKure Therapeutics (NASDAQ:OKUR) - Defense World
OnKure Elects Directors at Annual Stockholder Meeting - TipRanks
OnKure Therapeutics (NASDAQ:OKUR) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Major Stakeholders Shuffle Shares in OnKure Therapeutics - TipRanks
OnKure Therapeutics Inc (OKUR) At $2.00 Is Well Worth Your Time - Stocksregister
Barclays PLC Purchases New Stake in OnKure Therapeutics (NASDAQ:OKUR) - Defense World
Major Shareholder Sells Thousands of OnKure Therapeutics Shares! - TipRanks
Leerink Partnrs Issues Optimistic Outlook for OKUR Earnings - Defense World
Promising Developments and Positive Trial Results Reinforce Buy Rating for OnKure Therapeutics - TipRanks
OnKure increased R&D spending in 1Q with drug trials underway - BizWest
OnKure Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Form 424B3 OnKure Therapeutics, - StreetInsider
OnKure Therapeutics Reports Progress in PIKture-01 Trial and Financial Results for Q1 2025 - Nasdaq
OnKure Therapeutics, Inc. SEC 10-Q Report - TradingView
OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewswire
Head to Head Contrast: OnKure Therapeutics (NASDAQ:OKUR) & Anebulo Pharmaceuticals (NASDAQ:ANEB) - Defense World
Renaissance Technologies LLC Invests $408,000 in OnKure Therapeutics (NASDAQ:OKUR) - Defense World
OnKure Therapeutics (OKUR) Projected to Post Earnings on Tuesday - Defense World
OnKure Therapeutics (NASDAQ:OKUR) Research Coverage Started at Evercore ISI - Defense World
OnKure Therapeutics (NASDAQ:OKUR) Receives $32.33 Average Price Target from Brokerages - Defense World
Geode Capital Management LLC Makes New $659,000 Investment in OnKure Therapeutics (NASDAQ:OKUR) - Defense World
Q1 Earnings Estimate for OKUR Issued By Leerink Partnrs - Defense World
OnKure Therapeutics initiated with an Outperform at Evercore ISI - TipRanks
Evercore ISI Initiates Coverage on OnKure Therapeutics With Outperform Rating - marketscreener.com
Evercore ISI starts OnKure stock with Outperform rating - Investing.com
Evercore ISI starts OnKure stock with Outperform rating By Investing.com - Investing.com India
OKUR stock touches 52-week low at $2.49 amid market challenges - Investing.com
OnKure Therapeutics CEO sells $2,569 in stock - Investing.com Australia
OnKure Therapeutics CFO sells $9,177 in stock By Investing.com - Investing.com South Africa
OnKure Therapeutics CEO sells $2,569 in stock By Investing.com - Investing.com India
OnKure Therapeutics CFO sells $9,177 in stock - Investing.com
OKUR stock touches 52-week low at $3.39 amid market challenges - Investing.com Canada
OKUR stock touches 52-week low at $3.39 amid market challenges By Investing.com - Investing.com South Africa
We're Keeping An Eye On OnKure Therapeutics' (NASDAQ:OKUR) Cash Burn Rate - simplywall.st
OKUR stock touches 52-week low at $4.43 amid market challenges - Investing.com Australia
OKUR stock touches 52-week low at $4.43 amid market challenges By Investing.com - Investing.com South Africa
Q1 EPS Estimate for OnKure Therapeutics Lowered by Analyst - Defense World
OnKure Therapeutics (OKUR) Expected to Announce Quarterly Earnings on Thursday - Defense World
H.C. Wainwright cuts OnKure Therapeutics price target to $34 By Investing.com - Investing.com Australia
Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies - TipRanks
H.C. Wainwright cuts OnKure Therapeutics price target to $34 - Investing.com India
Promising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025 - TipRanks
Analyzing Organogenesis (NASDAQ:ORGO) and OnKure Therapeutics (NASDAQ:OKUR) - Defense World
OKUR stock touches 52-week low at $4.54 amid market challenges - Investing.com Australia
Onkure Therapeutics Inc (OKUR) 재무 분석
Onkure Therapeutics Inc (OKUR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Onkure Therapeutics Inc 주식 (OKUR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Leverone Jason A. | Chief Financial Officer |
Jun 23 '25 |
Sale |
2.38 |
303 |
722 |
12,906 |
| Cormorant Asset Management, LP | Former 10% Owner |
May 15 '25 |
Sale |
1.85 |
1,813,439 |
3,363,023 |
0 |
| ACORN BIOVENTURES, L.P. | 10% Owner |
May 15 '25 |
Buy |
1.85 |
1,129,730 |
2,090,000 |
1,129,730 |
| ACORN BIOVENTURES, L.P. | 10% Owner |
May 15 '25 |
Buy |
1.85 |
270,270 |
500,000 |
1,709,944 |
| Cormorant Asset Management, LP | 10% Owner |
May 12 '25 |
Sale |
1.99 |
24,300 |
48,236 |
1,813,439 |
| Saccomano Nicholas A | President and CEO |
Apr 07 '25 |
Sale |
2.67 |
516 |
1,378 |
3,682 |
| Saccomano Nicholas A | President and CEO |
Apr 04 '25 |
Sale |
3.33 |
358 |
1,191 |
4,198 |
| Leverone Jason A. | Chief Financial Officer |
Apr 07 '25 |
Sale |
2.67 |
1,844 |
4,925 |
13,209 |
| Leverone Jason A. | Chief Financial Officer |
Apr 04 '25 |
Sale |
3.33 |
1,278 |
4,253 |
15,053 |
| Leonard Braden Michael | 10% Owner |
Sep 25 '24 |
Buy |
1.50 |
68,746 |
102,872 |
3,457,395 |
0.68%
0.50%
자본화:
|
볼륨(24시간):